|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:approves
|
gptkb:2014
gptkb:FDA
|
|
gptkbp:atccode
|
L01 XX40
|
|
gptkbp:brand
|
gptkb:Ofev
gptkb:Vargatef
|
|
gptkbp:casnumber
|
656247-17-5
|
|
gptkbp:chemical_formula
|
C26 H29 N5 O4 S
|
|
gptkbp:class
|
indole derivatives
|
|
gptkbp:clinical_trial
|
Phase III
|
|
gptkbp:contraindication
|
pregnancy
severe liver impairment
lactation
|
|
gptkbp:developed_by
|
gptkb:Boehringer_Ingelheim
|
|
gptkbp:dosage_form
|
gptkb:capsule
|
|
gptkbp:duration
|
continuous
|
|
gptkbp:excretion
|
urine
feces
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Nintedanib
|
|
gptkbp:ingredients
|
gptkb:Nintedanib
|
|
gptkbp:initial_dose
|
150 mg daily
|
|
gptkbp:interacts_with
|
anticoagulants
antiplatelet agents
CYP3 A4 inducers
CYP3 A4 inhibitors
|
|
gptkbp:invention
|
patented
|
|
gptkbp:lifespan
|
10 hours
|
|
gptkbp:maintenance_dose
|
150 mg daily
|
|
gptkbp:marketed_as
|
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:mechanism_of_action
|
tyrosine kinase inhibitor
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:name
|
Essential Medicines
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:safety
|
Category D
|
|
gptkbp:side_effect
|
fatigue
nausea
hypertension
abdominal pain
diarrhea
gastrointestinal perforation
thromboembolic events
liver enzyme elevation
skin rash
pulmonary embolism
|
|
gptkbp:targets
|
gptkb:FGFR
gptkb:VEGFR
gptkb:PDGFR
|
|
gptkbp:used_for
|
gptkb:idiopathic_pulmonary_fibrosis
gptkb:Oncology
gptkb:systemic_sclerosis
|
|
gptkbp:bfsParent
|
gptkb:idiopathic_pulmonary_fibrosis
gptkb:VEGFR-2
|
|
gptkbp:bfsLayer
|
7
|